In cancer patients with malignant disease, skeletal muscle biopsies expressed increased Atrogin1 and MuRF1 levels even prior to weight and muscle loss [42], suggesting potential of Atrogin1 and MuRF1 as clinical biomarkers of cancer-mediated muscle wasting. This evidence concerns the gene FBXO32 and cancer.